The MATRIX SIGNED
Inflammatory resolution and remodelling of the adipose extracellular matrix: key determinants of a metabolically healthy phenotype?
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0The MATRIX project word cloud
Explore the words cloud of the The MATRIX project. It provides you a very rough idea of what is the project "The MATRIX" about.
Project "The MATRIX" data sheet
The following table provides information about the project.
| Coordinator |
GOETEBORGS UNIVERSITET
Organization address contact info |
| Coordinator Country | Sweden [SE] |
| Total cost | 1˙700˙002 € |
| EC max contribution | 1˙700˙002 € (100%) |
| Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
| Code Call | ERC-2018-STG |
| Funding Scheme | ERC-STG |
| Starting year | 2019 |
| Duration (year-month-day) | from 2019-09-01 to 2024-08-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | GOETEBORGS UNIVERSITET | SE (GOETEBORG) | coordinator | 1˙700˙002.00 |
Map
Project objective
Obesity and its affiliated metabolic diseases pose serious public-health challenges. However, certain patient subgroups appear protected. To halt the socio-economic burden of metabolic disease, we urgently need to understand what distinguishes the Metabolically-Healthy-Lean (MHL), Metabolically-Unhealthy-Lean (MUL), Metabolically-Healthy-Obese (MHO) and Metabolically-Unhealthy-Obese (MUO) phenotypes, and which factors promote metabolic health. Inflammation has been proposed as a target, as it is a key driver of metabolic disease. However, clinical trials show limited evidence that anti-inflammatory drugs reduce diabetes. Why is that?
Inflammation consists of a pro-inflammatory phase followed by a pro-resolving phase, which are regulated by different cells/pathways. This is critical to consider when attempting a therapeutic approach. Based on my preliminary data, I hypothesise that what separates MHL/MHO from MUL/MUO are not pro-inflammatory triggers, but rather the endogenous ability of individuals to resolve inflammation. Adipose extracellular-matrix remodelling appears critical, and pro-resolving lipids promote a MUO-to-MHO switch.
My overall goal is to determine molecular pathways that differentiate the MHL/MUL/MHO/MUO phenotypes (Aim 1-4), and to investigate the therapeutic potential of pro-resolving lipids (Aim 5). This multi-disciplinary project combines cutting-edge techniques with state-of-the-art translational approaches. Through my unique access to human biobanks, I will generate patient-specific cell-lines and test drug-targets ex vivo. Novel bioinformatics pipelines will produce protein/lipid/metabolite fingerprints associated with respective patient groups, ultimately providing a new approach to tackle obesity-related comorbidities. My experience in the specialised field of pro-resolving lipid biology, coupled with my lab’s unique placement at a translational site, makes me the right candidate to lead this research program.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THE MATRIX" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "THE MATRIX" are provided by the European Opendata Portal: CORDIS opendata.
